Joinn Laboratories China Co Ltd
SSE:603127
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12.46
23.86
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Joinn Laboratories China Co Ltd
Current Portion of Long-Term Debt
Joinn Laboratories China Co Ltd
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
J
|
Joinn Laboratories China Co Ltd
SSE:603127
|
Current Portion of Long-Term Debt
¥27.9m
|
CAGR 3-Years
17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Current Portion of Long-Term Debt
¥263.9m
|
CAGR 3-Years
15%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Pharmaron Beijing Co Ltd
SZSE:300759
|
Current Portion of Long-Term Debt
¥449.4m
|
CAGR 3-Years
61%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Current Portion of Long-Term Debt
¥1.1B
|
CAGR 3-Years
101%
|
CAGR 5-Years
103%
|
CAGR 10-Years
N/A
|
|
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Current Portion of Long-Term Debt
¥510.8m
|
CAGR 3-Years
23%
|
CAGR 5-Years
71%
|
CAGR 10-Years
N/A
|
|
|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Current Portion of Long-Term Debt
¥1.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Joinn Laboratories China Co Ltd
Glance View
Nestled in the bustling heart of China's vibrant biomedical sector, Joinn Laboratories China Co Ltd has emerged as a pivotal player in advancing the field of pharmaceutical research and development. Founded with a vision to revolutionize the landscape of drug testing and safety evaluation, Joinn Laboratories operates as a comprehensive preclinical contract research organization (CRO). The company specializes in providing a wide array of services including toxicology, pharmacology, and bioanalytical testing that are crucial in the early stages of drug development. With an expansive network of state-of-the-art laboratories and a team of highly skilled scientists, Joinn facilitates the essential task of ensuring that pharmaceutical products meet rigorous safety and efficacy standards before advancing to clinical trials. Joinn Laboratories generates revenue primarily by offering these indispensable services to pharmaceutical companies and biotech firms worldwide. By acting as an external testing partner, Joinn allows its clients to significantly streamline their drug development processes, reducing both time and cost associated with bringing a new drug to market. Their business model thrives on the growing demand for outsourced R&D capabilities, a trend fueled by the increasing complexity and regulatory requirements in drug approval processes. The company leverages its expertise and cutting-edge technology to deliver precise and reliable data, thus providing a seamless bridge between scientific discovery and market-ready pharmaceutical solutions.
See Also
What is Joinn Laboratories China Co Ltd's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
27.9m
CNY
Based on the financial report for Jun 30, 2024, Joinn Laboratories China Co Ltd's Current Portion of Long-Term Debt amounts to 27.9m CNY.
What is Joinn Laboratories China Co Ltd's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 3Y
17%
Over the last year, the Current Portion of Long-Term Debt growth was 3%. The average annual Current Portion of Long-Term Debt growth rates for Joinn Laboratories China Co Ltd have been 17% over the past three years .
You don't have any saved screeners yet
